NCT04537403

PET Detection of CCR2 in Human Atherosclerosis

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 89 Years
• Healthy volunteers: Accepted

Summary

: Use of novel radio-pharmaceutical 64CUDOTA-ECL1i to evaluate arterial atherosclrosis

Detailed description

Using 64CUDOTA-ECL1i to evaluate arterial atherosclrosis in normal volunteers and patients with carotid or femoral arterial atherosclerosis..

Conditions

• Carotid Atherosclerosis

Interventions

Type	Name	Description
DRUG	Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)	Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
DRUG	Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)	Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart

Timeline

• Start date: 2020-10-01
• Primary completion: 2025-09-01
• Completion: 2025-09-01
• First posted: 2020-09-03
• Last updated: 2025-08-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study